Priority Healthcare b (NASDAQ:PHCC)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Priority Healthcare b Charts. Click Here for more Priority Healthcare b Charts.](/p.php?pid=staticchart&s=N%5EPHCC&p=8&t=15)
Priority Healthcare Corporation Announces Availability of Generic
Ribavirin Hepatitis C Treatment
LAKE MARY, Fla., April 7 /PRNewswire-FirstCall/ -- Priority Healthcare
Corporation announced that generic ribavirin, approved yesterday by the FDA for
the treatment of hepatitis C, will be available from the company's specialty
pharmacy operation today.
"Ribavirin, used in combination with interferon, is the leading treatment for
hepatitis C. It is our hope that the launch of generic ribavirin will result in
increased awareness and treatment options for the 4 million Americans who suffer
from this disease. As the market leader in this disease area, we are very
pleased that patients can obtain ribavirin combined with our customized care
services," said Kim Rondeau, Executive Vice President, Pharmacy Sales &
Marketing for Priority Healthcare.
Priority Healthcare offers a supportive disease treatment management program for
hepatitis C patients that includes:
* One-on-one nurse counseling and educational information at the initiation of
treatment
* Caring Paths(TM) disease treatment management process, specific to hepatitis
* Access to pharmacists and nurses 24 hours a day/7 days a week to answer
patient questions
* Monthly check-ins with patient care coordinators who follow up with physicians
as needed
* Ongoing educational disease information, support networks, chats with disease
specialists, and research and treatment updates available as a free community
resource at Priority Healthcare's Hepatitis Neighborhood at
http://www.hepatitisneighborhood.com/
About Hepatitis C
According to the National Institutes of Health, hepatitis C virus (HCV) is one
of the most important causes of chronic liver disease in the United States and
is the leading indication for liver transplants. Since 80% of hepatitis C
patients have no signs or symptoms, it is important to increase awareness and
education of the disease.
Hepatitis C affects 4 million Americans, or 1.8% of the population, and causes
an estimated 10,000-12,000 deaths annually in the United States. Hepatitis is
transmitted by blood and blood products. People most at risk are those who have
had blood transfusions before 1992, injection drug users, infants born to
HCV-infected mothers, healthcare workers who suffer needle sticks, and people
exposed to blood products, including patients with hemophilia, solid-organ
transplants, chronic renal failure, or cancer requiring chemotherapy.
Currently, the optimal treatment appears to be a 24- or 48-week course of
combination pegylated alpha interferon and ribavirin. (The information on
hepatitis C is from the National Institutes of Health available online at
http://digestive.niddk.nih.gov/ddiseases/pubs/chronicchepc/index.htm)
About Ribavirin
Ribavirin is an anti-viral drug known as a nucleoside analogue. Ribavirin
disrupts viral RNA and DNA synthesis, which slows down or stops the virus from
replicating. Ribavirin is prescribed in combination with interferon for
hepatitis C. It is not effective or approved as a monotherapy against HCV. For
people who have medical conditions that would not allow the use of ribavirin,
such as heart disease and anemia, interferon medication may be used alone
(monotherapy). Patients should talk with their physician to learn more about
ribavirin and interferon therapies.
About Priority Healthcare Corporation
Priority Healthcare Corporation is a national specialty pharmacy and distributor
that provides biopharmaceuticals, complex therapies, and related disease
treatment services. Priority Healthcare provides comprehensive programs for
patients, payors, physicians, and pharmaceutical manufacturers for a growing
number of disease states including cancer, hepatitis C, respiratory and
pulmonary conditions, infertility, rheumatoid arthritis, hemophilia, multiple
sclerosis, and macular degeneration. Additional information regarding Priority
Healthcare is available online at http://www.priorityhealthcare.com/
Certain statements included in this press release, which are not historical
facts, are forward-looking statements. Such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements represent our expectations
or beliefs and involve certain risks and uncertainties, including those
described in our public filings with the United States Securities and Exchange
Commission; also including, but not limited to, changes ininterest rates,
competitive pressures, changes in customer mix, changes in third party
reimbursement rates, financial stability of major customers, changes in
government regulations or the interpretation of these regulations, changes in
supplier relationships, growth opportunities, cost savings, revenue
enhancements, synergies and other benefits anticipated from acquisition
transactions, difficulties relative to integrating acquired businesses, the
accounting and tax treatment of acquisitions, and asserted and unasserted
claims, which could cause actual results to differ from those in the
forward-looking statements. The forward-looking statements by their nature
involve substantial risks and uncertainties, certain of which are beyond our
control, and actual results may differ materially depending on a variety of
important factors. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date herein.
http://www.newscom.com/cgi-bin/prnh/20030417/PHCLOGO
http://photoarchive.ap.org/
DATASOURCE: Priority Healthcare Corporation
CONTACT: Stephen Saft, Chief Financial Officer, +1-407-804-6700, or
Media, Kirsten Ayars, Public Relations Manager, +1-407-804-5826, both of
Priority Healthcare Corporation
Web site: http://www.priorityhealthcare.com/
http://www.hepatitisneighborhood.com/